RETA - Reata Pharmaceuticals, Inc. Price-to-Projected Revenue Ratio

Developing drugs for rare pathologies requires colossal expenditures and FDA approval, which is reflected in the forward P/S ratio. The growth of this metric is driven by the implementation of IT platforms for analyzing brain degeneration, while the 233.60 level records fresh values. Current price action is explained by the acquisition of Reata Pharmaceuticals (RETA) by an industry leader to facilitate the global market launch of the breakthrough drug Skyclarys.

Reata Pharmaceuticals Inc - RETA Projected Price to Revenue (period 07/04/2022 - 10/07/2023)

Comprehensive metric breakdowns and analytics for Reata Pharmaceuticals (RETA)

- market price and analyst price targets:

Price Chart Reata|RETA - Price Target Chart

- market capitalization statistics:

Market Value Reata Pharma|RETA - Total Enterprise Value

- book value of equity indicators:

Book Value per Share Reata Pharmaceuticals|RETA - Book Value of Business|Market Cap to Net Assets Ratio reatapharma.com|RETA - Company Assets

- debt and liquidity data:

- financial results and valuation multiples details:

RETA - Net Profit|Future Profit Reata Pharmaceuticals|RETA - Company Value to Net Income|Future Price to Earnings Reata|RETA - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Reata Pharmaceuticals Inc|RETA - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Reata Pharmaceuticals|RETA - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months reatapharma.com|RETA - Earnings per share increase in current year|Net earnings per share growth forecast for next year Reata Pharmaceuticals

- revenue and sales proceeds data:

RETA - Company Sales|Projected Sales Volume Reata Pharmaceuticals Inc|RETA - P/S Multiple|Forward P/S Multiple Reata Pharmaceuticals Inc

Initial company analysis:Reata Pharmaceuticals Inc RETA

The forward P/S ratio assesses the market value of the business relative to expected revenue, revealing the impact of cost inflation and pressure on operating margins during periods of market volatility. For Reata Pharmaceuticals (RETA), this chart's trend confirms capitalization resilience driven by the indispensable demand for Skyclarys, which serves as a steady cash generator and offsets the risks of an operational downturn.

Competitors of Reata Pharmaceuticals

Price-to-Projected Revenue Ratio Jazz Pharma JAZZ|Cytokinetics Corp - Price-to-Projected Revenue Ratio|PTCT - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Scholar Rock|CNTA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Dyne Therapeutics (DYN)|Forward Price-to-Revenue Multiple EWTX|Market Cap to Future Revenue Ratio Rapport Corp RAPP|Forward P/S Multiple ALMS|ZVRA: Future Price to Revenue|Price-to-Projected Revenue Ratio Contineum Corp CTNM|Forward P/S Multiple Larimar Therapeutics Inc LRMR|CAPR - Price-to-Projected Revenue Ratio|Entrada Therapeutics, Inc - Price to Expected Revenue Ratio|Channel Therapeutics Corp (PTHS) - Price-to-Projected Revenue Ratio|MNOV - Market Cap to Expected Sales Ratio|SER (serinatherapeutics.com) - Forward P/S Multiple|Forward Price-to-Revenue Multiple BioXcel Therapeutics, Inc. (BTAI)|Forward Price-to-Revenue Multiple PMN (ProMIS Neurosciences Inc.)|Apimeds Pharmaceuticals, Inc. - Market Cap to Projected Revenue|Forward P/S Multiple AEON (aeonbiopharma.com)|Forward P/S Multiple NLS Pharmaceutics AG NLSP|Bionomics - Forward P/S Multiple|Forward Price to Sales HUGE (fsdpharma.com)